Abstract
Background Nasopharyngeal samples (NPS) are the mainstay of COVID-19 diagnosis. However, the extent to which assay signals relate to exhaled virus is unknown. We investigated the use of novel, non-invasive face-mask sampling (FMS) to detect exhaled SARS-CoV-2 RNA in two studies.
Methods In an outbreak study (cohort 1), we performed FMS and NPS for 21 consecutive days after diagnosis on six healthcare workers who were screened positive for SARS-CoV-2. In a second hospitalised cohort (cohort 2), we performed FMS on 47 patients within 24 hours of a positive diagnosis. COVID-19 severity was graded according to WHO recommendations.
Findings In cohort 1, SARS-COV-2 was detected by FMS in 10/40 (25%) samples (4/6 individuals), with no correlation between NPS and FMS RNA signals. All samples were negative by day 14 post diagnosis. Sustained FMS positivity with higher viral RNA signals showed a trend towards disease severity.
In cohort 2, 19/47 (40%) individuals exhaled SARS-CoV-2 RNA extending over five orders of magnitude. FMS positive participants were older (positive: median age [IQR] 71 [61–84] vs negative: 61 [45–73], p = 0.04) with more comorbidities (positive: 2 [1–3] vs negative: 1 [0–2], p< 0.001) and have active cough (positive: 68% vs negative: 24%, p = 0.003) and breathlessness (positive: 74% vs negative: 32%, p = 0.005) during sampling, compared to FMS negative patients. Of five patients who were FMS positive and asymptomatic at time of sampling, two died of severe COVID-19 pneumonia within one month of follow up.
Interpretation FMS detects exhaled SARS-COV-2, with stronger signals in those who develop severe disease.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04481646
Funding Statement
MP is funded by a NIHR Development and Skills Enhancement Award and is supported by NIHR Leicester Biomedical Research Centre (BRC). DP and SS are supported by the NIHR. Funding for this project came from the University of Leicester LD3/MRC CiC for access to the CBS C3 Facility and for funding from the UniveristyLD3/MRC CiC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health Research Authority (20/WM/0153).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual participant data will be available that underlie the results reported in this article after de-identification along with the study protocol between 9-36 months post publication.
